Latest development in viral vectors for gene therapy (Q35082177)

6 August 2017

1 reference

title

Latest development in viral vectors for gene therapy (English)

1 reference

6 August 2017

0 references

Kenneth Lundstrom

1

1 reference

6 August 2017

publication date

1 March 2003

1 reference

6 August 2017

published in

Trends in Biotechnology

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

117-122

1 reference

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Outcry greets US plan to test smallpox vaccine on children

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Points to consider for ethics committees in human gene therapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Adeno-associated virus expression systems for gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Alphavirus vectors for gene therapy applications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

HSV1716 persistence in primary human glioma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Gene transduction efficiency in cells of different species by HIV and EIAV vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Stable suppression of gene expression by RNAi in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

Gene silencing in mammals by small interfering RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

siRNA-mediated gene silencing in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2802%2900042-2

7 January 2021

10.1016/S0167-7799(02)00042-2

Identifiers

DOI

1 reference

6 August 2017

1 reference